Sun Pharma will set-up a dengue vaccine advisory group to provide technical and regulatory support to the vaccine development programme
International Centre for Genetic Engineering and Biotechnology (ICGEB) and Sun Pharma recently announced their collaboration for development of a dengue vaccine, targeted against all the four serotypes of dengue virus that cause disease in humans.
ICGEB has developed a tailored recombinant virus-like-particle (VLP)-based tetravalent dengue vaccine, containing host-receptor binding domain of envelope protein of all the four DENV serotypes. ICGEB has conducted pre-clinical studies over the past seven years and developed the existing know-how and patents for this dengue vaccine candidate.
Sun Pharma will set-up a dengue vaccine advisory group to provide technical and regulatory support to the vaccine development programme. Reportedly, it will also be exclusively responsible for all Regulatory filings for the product globally including, without limitation, CDSCO-India, WHO, US FDA, EMA, MHRA etc. The company will explore commercialisation opportunities to provide this vaccine to patients across India, emerging markets, western Europe, Japan and the US at affordable costs post regulatory approvals in these markets.
Sun Pharma will use its in-house expertise as well as expertise of its Associate company, ARTES Biotechnology, in development of dengue vaccine. ARTES will add their experience and proprietary know-how in production of VLP-based vaccines from yeast production cell lines. Hep-B and HPV vaccines developed by ARTES are licensed to several companies worldwide and a malaria vaccine programme is sponsored by PATH.
EP News Bureau